<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01127555</url>
  </required_header>
  <id_info>
    <org_study_id>CAUHHO 2010-2</org_study_id>
    <nct_id>NCT01127555</nct_id>
  </id_info>
  <brief_title>Salvage mFOLFOX in BTC After Failure of Gemcitabine</brief_title>
  <official_title>Phase II Study of Salvage mFOLFOX(5-fluorouracil, Leucovorin, Oxaliplatin) in Patients With Unresectable Biliary Tract Cancer (BTC) Who Had Failed Gemcitabine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chung-Ang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gyeongsang National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dong-A University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chung-Ang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of mFOLFOX (5-fluorouracil,
      leucovorin, oxaliplatin)as salvage therapy in patients with unresectable biliary tract cancer
      who had failed gemcitabine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>1 year</time_frame>
    <description>Clinically assessed every cycle (2weeks) and radiologically assessed every 3 cycles (6 weeks) with CT scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety</measure>
    <time_frame>1 year</time_frame>
    <description>Clinically assessed every cycle (2weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the time to progression</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Unresectable Biliary Tract Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil, leucovorin, oxaliplatin</intervention_name>
    <description>D1 Oxaliplatin 85mg/m2 D1, 2 LV 30mg/m2 IV push D1, 2 5-FU 1500mg/m2 CIV over 24hrs Every 2 weeks</description>
    <other_name>mFOLFOX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age : older than 18

          2. Histologically confirmed adenocarcinoma of the biliary tract

          3. Metastatic or unresectable biliary cancer

          4. Prior exposure to gemcitabine chemotherapy for biliary cancer

          5. Eastern Cooperative Oncology Group (ECOG) performance status 0 -2

          6. A patient with at least one measurable primary lesion of which the diameter is
             confirmed to be 10mm in spiral Computed Tomography (CT) or multidetector CT

          7. Adequate bone marrow, liver, renal function

        Exclusion Criteria:

          1. Pregnancy and breast-feeding.

          2. Other serious illness or medical condition, notably heart or lung failure, active
             uncontrolled infection (infection requiring antibiotics).

          3. Past or concurrent history of other neoplasm, except curatively treated basal cell
             skin cancer or adequately treated in-situ carcinoma of the cervix.

          4. Symptomatic or uncontrolled brain metastasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In Gyu Hwang, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Chung-Ang University Yongsan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chung-Ang University Yongsan Hospital</name>
      <address>
        <city>Yongsan</city>
        <state>Seoul</state>
        <zip>140-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2010</study_first_submitted>
  <study_first_submitted_qc>May 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2010</study_first_posted>
  <last_update_submitted>October 6, 2013</last_update_submitted>
  <last_update_submitted_qc>October 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chung-Ang University</investigator_affiliation>
    <investigator_full_name>In Gyu Hwang</investigator_full_name>
    <investigator_title>Chung-Ang University Hospital</investigator_title>
  </responsible_party>
  <keyword>Biliary Tract Cancer</keyword>
  <keyword>Salvage therapy</keyword>
  <keyword>FOLFOX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

